TWAICE
31.3.2021 12:14:12 CEST | Business Wire | Press release
TWAICE provides predictive analytics software that optimizes the development and operation of batteries. For the energy sector this means enhanced transparency and predictability of stationary battery storages. The results are optimized storage operations and reduced technology risks. The battery experts are now expanding their portfolio with an Operating Strategy Planner, a surefire method to extract maximum profit from stationary energy storages.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210331005480/en/
Major utility companies are among the first customers to connect to the Operating Strategy Planner. According to Stephan Rohr, Co-CEO at TWAICE, others will soon follow suit: “There has been huge interest in the Operating Strategy Planner, which empowers owner and operator decision-making to deliver significant increases in return on investment for energy storage portfolios. We are delighted to have major utilities as first customers of this cutting-edge new product”.
Batteries are pivotal to the success of renewable energy. Their capacity to store and generate energy on demand is unique. It makes them a vital element of the storage solutions required to stabilize grids in the face of fluctuating and decentralized energy generation. As highly complex systems, batteries must be expertly managed if optimum performances are to be consistently delivered. The key: transparency into battery aging behavior.
Stationary energy storage use cases and operational constraints have differing effects on battery degradation. This has a large impact on the individual business case and risk profile. The TWAICE Operating Strategy Planner enables users to create scenarios and conduct sensitivity analyses for different use cases and boundary conditions. They can compare the scenarios and find the optimum and learn how long the storage will last with the selected strategy.
The software empowers storage operators and owners to achieve optimal returns under consideration of battery health. This means deploying sophisticated multi-use strategies and identifying the right mix, for example of intraday trading and frequency response. The algorithms that market the capacity of battery storages are provided with the most profitable boundary conditions for operation. The opportunity costs of each trade can be assessed, and the profits are maximized. All of this, while reducing the overall risk of unexpected battery aging over the lifetime.
TWAICE provides analytics software that optimizes the development and operation of lithium-ion batteries. TWAICE’s core technology is a software that combines deep battery knowledge and artificial intelligence to determine the condition and predict the aging and performance of batteries. As the leading battery analytics software for players in the mobility and energy sectors, TWAICE is committed to increasing the lifetime, efficiency, reliability, and sustainability of the products that power the economy of tomorrow.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210331005480/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 07:00:00 CEST | Press release
Galderma received a Complete Response Letter from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization Relfydess is approved in 33 markets and already launched in more than 20, including across Europe, the Middle East and Australia, with an encouraging early launch trajectory supported by positive healthcare professional feedback Regulatory filings in other territories are ongoing and remain on track Ad hoc announcement pursuant to Art. 53 LR Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufa
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 03:45:00 CEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom